HitGen Inc. is a rapidly developing biotech company headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. It became a publicly listed company in Shanghai Stock Exchange in April 2020 (ticker code 688222.SH). HitGen has established a drug discovery research platform for small molecules and nucleic acid drug centered on the design, synthesis and screening of DNA encoded chemical libraries (DELs), fragment-based drug discovery (FBDD) and structure-based drug design (SBDD) technologies. HitGen's DELs currently contains more than 1 trillion novel, diverse, drug-like small molecules and macrocyclic compounds. These compounds are members of DELs synthesized from many hundreds of distinct chemical scaffolds, designed with tractable chemistry, and have yielded proven results for the discovery of small molecule leads against precedented and unprecedented classes of biological targets.
Through its acquisition of Cambridge UK based Vernalis R&D Ltd before the end of 2020, a leader in FBDD/SBDD, HitGen now has a research team of over 500 scientists and offers a full set of research capabilities from recombinant protein expression and purification, structural biology, assay development, screening, DEL synthesis, nucleic acid and small molecule chemical synthesis, computational and medicinal chemistry, biochemistry and biophysics, cell biology, in vivo pharmacology, DMPK, CMC, etc., to enable drug discovery research from target gene to IND filing.
HitGen operates a flexible business model, ranging from a single capability-based fee for services (FFS，e.g., protein expression and purification, structural biology, bioinformatics, computational chemistry, medicinal chemistry, nucleic and organic chemistry, analytical chemistry，biophysics, PK, PD, etc.), DEL screening, DEL design, synthesis and characterization, integrated drug discovery projects, risk sharing projects, collaborative ventures to program out-licensing. HitGen has approximately 20 in-house drug discovery programs at different stages of research & development. HitGen is collaborating with pharmaceutical, biotech and chemical companies, foundations and research institutes in North America, Europe, Asia, Africa and Australia to enable the discovery and development of novel medicines and agrochemicals.
| Full name | HitGen Inc. |
|---|---|
| Abbreviations | HitGen |
| Code | 688222 |
| Founded | 2012-02-22 |
| Listing | 2020-04-16 |
| Domicile | Chengdu |
| Website | https://www.hitgen.com/ |
| investors@hitgen.com | |
| STAR Theme | Biomedicine |
| CSRC Sector | Scientific research and technical service |
| Has weighted voting rights structure? | No |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Earnings Per Share | 0.17 | 0.33 | N/A |
| R&D expenditure as a % of operating revenue | 41.00% | 34.62% | 40.92% |
| Operating Revenue | 243.60 | 264.20 | 151.20 |
| Net Income | 64.02 | 120.27 | 44.96 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Operating Revenue | 243.60 | 264.20 | 151.20 |
| Operating Costs | 50.27 | 48.75 | 26.21 |
| Operating Income | 59.57 | 132.89 | 48.86 |
| Pretax Income | 63.36 | 132.82 | 48.92 |
| Income Tax | -0.67 | 12.55 | 3.96 |
| Net Income | 64.02 | 120.27 | 44.96 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Assets | |||
| Current Assets-Total | 1,145.31 | 487.42 | 355.95 |
| Non-current Assets-Total | 502.70 | 147.93 | 156.13 |
| Total Assets | 1,648.01 | 635.35 | 512.08 |
| Liabilities | |||
| Current Liabilities-Total | 221.00 | 72.95 | 101.51 |
| Non-current Liabilities-Total | 149.08 | 50.63 | 20.90 |
| Total Liabilities | 370.08 | 123.58 | 122.41 |
| Stockholder's Equity | |||
| Share Capital | 1,151.92 | 403.14 | 453.59 |
| Retained Profits | 126.01 | 108.64 | -63.92 |
| Total Owners' Equity | 1,277.93 | 511.77 | 389.67 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Net Cash Flows-Operating | 1.59 | 168.25 | 50.70 |
| Net Cash Flows-Investing | -696.73 | -35.92 | -129.41 |
| Net Cash Flows-Financing | 801.88 | -5.22 | 251.06 |
| Name | No. of Shares Held (mn) | % of Shares Held |
|---|---|---|
| JIN LI | 81.88 | 20.43% |
| Lhasa Huabo Health Development Co., Ltd | 59.15 | 14.76% |
| 成都聚智科创生物科技合伙企业（有限合伙） | 38.65 | 9.65% |
| 安吉东方佳钰投资合伙企业（有限合伙） | 37.67 | 9.40% |
| CentralSKY Investment（Limited Partnership） | 37.67 | 6.00% |
| 成都腾澜生物技术合伙企业（有限合伙） | 21.97 | 5.48% |
| Jumbo Kindness Limited | 19.93 | 4.97% |
| 重庆渤溢新天股权投资基金合伙企业（有限合伙） | 18.00 | 4.49% |
| 嘉兴丹青投资合伙企业（有限合伙） | 16.97 | 4.23% |
| 杭州鼎晖新趋势股权投资合伙企业（有限合伙） | 14.57 | 3.64% |
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.